ILMN

T2S&P 500Health Care (XLV)Momentum (MTUM)Value (IWD)Innovation (ARKK)

Illumina, Inc.

Next est. report 2026-10-29 · AMC

Cycle Long '24: Health & Life Sciences Genomics '25: Sequencing Platforms & Instruments MedTech Long '25: Diagnostic Platforms MedTech Long '26: Diagnostics & Early Detection MedTech Long '26: Life Science Tools & Bioprocessing

Loading…

Loading chart…

Overview

Illumina, Inc. provides tools, including NovaSeq X sequencers and related chemicals, to "read" genetic information for research and clinical use. These help und

Illumina, Inc. provides tools, including NovaSeq X sequencers and related chemicals, to "read" genetic information for research and clinical use. These help understand diseases, develop drugs, and improve health. Sequencing consumables make up about 67% of revenue, instruments 11%, services 13%, and microarrays 9%. They sell to research labs, hospitals, and biotech companies worldwide.

Key Inputs And Sourcing

1. Reagents/Consumables Materials

Not in registry

other · Global · ~40-50% of total COGS

Source Sequencing consumables are Illumina's largest revenue segment (~66.8% of total revenue in Q2 2026). These kits include reagents, buffers, and other specialized chemical/biological materials. The cost of producing these is a significant portion of consumables revenue.

Confidence: high

2. Electronic Components

Not in registry

component · Global, likely East Asia · unknown

Source Mentioned as 'critical components' for instruments. Illumina's supply chain involves sourcing these, and the company secured additional inventory for several quarters.

Confidence: high

3. Memory Costs

Not in registry

component · Global · unknown

Source Explicitly cited as a 'headwind' impacting gross margin in Q2 2026. Illumina absorbed higher memory costs and secured supply.

Confidence: high

4. Freight Costs

Not in registry

logistics · containerized-freight-index · Global · unknown

Source Explicitly cited as a 'headwind' impacting gross margin in Q2 2026. Illumina absorbed higher freight costs.

Confidence: high

5. Flow Cells

Not in registry

component · Global · unknown

Source An integral, specialized component of sequencing consumables, included in reagent kits for NovaSeq X and other systems.

Confidence: high

6. Labor (Manufacturing & R&D)

Not in registryaccess=api

labor · Global · unknown

Source Illumina has significant manufacturing operations and R&D expenses, contributing to COGS and operating expenses. The company has approximately 8,970 employees.

Confidence: medium

7. Compute Infrastructure/Power

Not in registry

other · Global (cloud services, data centers) · unknown

Source Essential for BioInsight, data analysis, and AI-enabled drug discovery, representing a growing cost input.

Confidence: medium

8. Packaging

Not in registry

packaging · Global · unknown

Source Instruments and consumables require packaging for shipment and storage.

Confidence: low

Industry Publications

GenomeWeb (genomeweb.com) — Provides comprehensive news and analysis on the genomics industry, including sequencing technology, clinical applications, research advancements, and business developments, directly impacting Illumina's market.
Nature Genetics (nature.com) — A leading scientific journal publishing significant research in genetics and genomics, often featuring studies that utilize or influence sequencing technologies, indicating emerging trends and scientific validation relevant to Illumina's R&D.
Clinical Laboratory News (CLN) (myadlm.org) — Focuses on clinical laboratory medicine, including molecular diagnostics, regulatory updates, and emerging technologies, which are critical for Illumina's clinical market segment.
Fierce Biotech (fiercebiotech.com) — Offers news and analysis on biotech and pharma R&D, including drug discovery, clinical trials, and AI integration, relevant to Illumina's multi-omics and BioInsight initiatives.
Technology Networks - Spatial Biology (technologynetworks.com) — Provides the latest news, articles, and insights specifically on spatial biology, a key area of expansion for Illumina with products like StrataMap Spatial.

Economic Data Watch

1. FRED — National Health Expenditure Accounts (NHEA)

Not in registryaccess=api

Metric/field Total Health Expenditures

Cadence quarterly

Why it matters Overall healthcare spending indicates the market size and health for diagnostic services, directly impacting the addressable market for Illumina's clinical applications.

Signal to watch Increasing expenditures suggest a growing market.

Confidence: low

2. NIH, Public Records — NIH Budget and Spending

Not in registry

Metric/field Total NIH Funding (Budget Authority)

Cadence annually

Why it matters Indicates investment and focus on genomics technologies, directly impacting Illumina's research and academic market segment, which has shown caution due to funding uncertainty.

Signal to watch Increase in funding suggests potential recovery or growth in research markets.

Confidence: high

3. FRED — National Income and Product Accounts

Not in registryaccess=api

Metric/field Gross Domestic Product (GDP) (chained dollars, annual rate) (GDPC1)

Cadence quarterly

Why it matters A strong economy can lead to increased funding for research and development, and greater investment in healthcare infrastructure, benefiting Illumina's diverse customer base.

Signal to watch Sustained or accelerating GDP growth is positive.

Confidence: high

4. BLS — Consumer Price Index

Not in registryaccess=api

Metric/field All Urban Consumers: All Items in U.S. City Average (CPIAUCSL)

Cadence monthly

Why it matters High inflation, particularly in freight and electronic components, directly impacts Illumina's cost of goods sold and operating expenses, potentially squeezing margins, as noted in recent earnings.

Signal to watch Moderating or declining inflation is positive for cost management.

Confidence: high

5. Federal Reserve Board — Industrial Production and Capacity Utilization

Not in registry

Metric/field Industrial Production: Manufacturing (IPMAN)

Cadence monthly

Why it matters Healthy manufacturing activity can indicate stable supply chains and demand for components, which are crucial for Illumina's instrument production, especially given past supply investments.

Signal to watch Stable or increasing manufacturing production is positive.

Confidence: high

Free Alt Data Watch

1. ClinicalTrials.gov — Clinical Trial Registry

Not in registry

Metric/field Number of new studies with 'next generation sequencing' OR 'genomics' OR 'multi-omics' in study title/description (Recruiting status)

Cadence daily

Why it matters Indicates the expanding application of sequencing technologies in clinical research, which drives demand for Illumina's instruments and consumables, particularly in clinical markets.

Signal to watch Increasing number of new trials suggests growing adoption and future market expansion.

Confidence: high

2. USPTO PatentsView — Patent Grants and Applications

Not in registry

Metric/field Number of patents granted/applications published by 'Illumina Inc.' related to 'sequencing', 'multi-omics', 'spatial biology', 'proteomics', or 'AI drug discovery'

Cadence weekly

Why it matters Reflects Illumina's ongoing innovation and competitive positioning in key strategic areas like multi-omics and AI-enabled drug discovery, which are central to its growth strategy.

Signal to watch Consistent or increasing patent activity indicates strong R&D and future product pipeline.

Confidence: high

3. Google Trends — Search Interest

Not in registry

Metric/field Search term volume for 'NovaSeq X' OR 'StrataMap Spatial' OR 'SomaScan' OR 'Billion Cell Atlas' (Worldwide)

Cadence weekly

Why it matters Indicates public and professional interest and awareness in Illumina's key products and strategic initiatives, signaling potential market adoption and demand.

Signal to watch Rising search interest suggests growing market awareness and potential demand for Illumina's offerings.

Confidence: medium

4. SEC EDGAR — Form 8-K Filings

Not in registry

Metric/field Number of 8-K filings by ILMN related to 'customer agreements', 'partnerships', or 'product launch'

Cadence event_driven

Why it matters Provides real-time insights into significant business developments such as new customer wins, strategic collaborations (e.g., Billion Cell Atlas partners), or product introductions.

Signal to watch Increased filings related to customer agreements or product launches indicate business momentum and successful execution of strategy.

Confidence: high

5. Illumina Investor Relations — Press Releases / Newsroom

Not in registry

Metric/field Announcements of new NovaSeq X placements, multi-omics product updates, or BioInsight partnerships

Cadence irregular

Why it matters Directly communicates key operational successes and strategic progress, such as NovaSeq X placements and the expansion of multi-omics and AI-enabled drug discovery initiatives.

Signal to watch Frequent positive announcements indicate strong business execution and market traction.

Confidence: high

Paid Alt Data Watch

1. IQVIA — Medical Claims Data

Matchediqvia_medical_claims · access=file · map_only

Metric/field CPT code utilization for molecular diagnostic tests (e.g., specific codes for liquid biopsy, MRD, MCED) in oncology and rare diseases

Cadence monthly

Why it matters Provides granular, independent data on actual test utilization, market share, and reimbursement trends for sequencing-based diagnostics, directly reflecting demand for Illumina's clinical consumables.

Signal to watch Increasing CPT code utilization indicates growing adoption of sequencing in clinical settings.

Confidence: high

2. YipitData — Medtech Product Procurement Data

Matchedyipitdata_hospital_purchasing_medtech_procurement · access=file · map_only

Metric/field Hospital/surgical-center purchasing data for Illumina instruments (e.g., NovaSeq X, MiSeq i100) and consumables

Cadence monthly

Why it matters Offers direct insights into instrument placements and consumable pull-through at the institutional level, providing an early indicator of revenue trends and market penetration.

Signal to watch Consistent or increasing procurement of Illumina products suggests strong demand and expanding installed base.

Confidence: high

3. Similarweb — Web Traffic & Engagement Data

Matchedsimilarweb_website_traffic_engagement · access=file · map_only

Metric/field Website traffic (visits, unique visitors) to illumina.com and specific product pages (e.g., NovaSeq X, StrataMap Spatial)

Cadence monthly

Why it matters Provides a proxy for customer interest and engagement with Illumina's products and services, potentially correlating with sales pipeline and market awareness.

Signal to watch Rising website traffic and engagement indicate increasing interest in Illumina's offerings.

Confidence: medium

4. Definitive Healthcare — All-Payer Medical Claims & Hospital Data

Matcheddefinitive_healthcare_medical_claims_procedures · access=file · map_only

Metric/field Number of hospitals/labs adopting NGS technologies and their patient volumes for relevant conditions (e.g., oncology, rare diseases)

Cadence quarterly

Why it matters Offers insights into the expansion of the addressable market and the penetration of NGS technologies within clinical institutions, supporting Illumina's primary growth driver.

Signal to watch Increasing adoption of NGS and patient volumes in target clinical areas are positive.

Confidence: high

5. Consumer Edge — Healthcare Facilities Procurement Data (Taurus)

Matched (medium)consumer_edge_hospital_purchasing_procurement · access=file · map_only

Metric/field Spending trends by healthcare facilities on 'sequencing reagents' or 'genomic analysis equipment' from Illumina

Cadence monthly

Why it matters Provides detailed transaction-level data on actual purchases of consumables and equipment by healthcare facilities, offering a granular view of demand and pull-through.

Signal to watch Growth in spending on Illumina's consumables and equipment indicates strong product utilization and market demand.

Confidence: high

Search Keywords Brand Product

NovaSeq X
StrataMap Spatial
SomaScan
SomaSeq
BioInsight
Billion Cell Atlas
whole genome MRD research workflow
MiSeq i100
TruPath
next-generation sequencing
NGS instruments
genomic analysis
clinical diagnostics
multi-omics
spatial biology
proteomics
AI drug discovery
cancer screening
rare disease testing
NIPT

Search Keywords Event Phrases

Illumina earnings
NovaSeq X placements

Search Keywords Policy Regulatory

Medicare coverage diagnostics
MCED Act

What They Do (Plain English & Analogies): Illumina is like a high-tech detective agency for your genes. They create specialized tools and chemicals that scientists and doctors use to "read" the entire genetic instruction book (DNA) of a person, animal, or plant. This helps them understand what makes us unique, what causes diseases like cancer, how to develop new medicines, or even how to improve crops. They provide the "microscopes" (sequencing machines like the NovaSeq X) and the "slides and stains" (reagents and arrays) to uncover these genetic secrets. They also offer services to help analyze the massive amounts of data generated, and are now expanding into tools that look at other biological information beyond just DNA, like proteins and how cells are organized in tissues, to get an even fuller picture of biology.
Very Brief History: Illumina, Inc. was founded in April 1998 and is headquartered in San Diego, California. Since its inception, the company has focused on developing and commercializing integrated systems for genetic analysis, evolving into a global leader in sequencing and array technologies. Key milestones include the continuous innovation of its sequencing platforms, such as the NovaSeq X, and strategic expansions into multi-omics capabilities through acquisitions like SomaLogic and internal developments like BioInsight.
"Street Stereotype": Illumina is generally perceived as the dominant incumbent in the next-generation sequencing (NGS) hardware and consumables market. It's seen as the foundational technology provider for much of the global genomics research and clinical testing infrastructure, particularly for liquid biopsy and multi-omics. While facing increasing competition, especially in lower-cost sequencing, its NovaSeq X platform is viewed as a key driver for future growth and maintaining its market leadership.
Subsidiaries On Linked In*: Illumina GmbH — German subsidiary mentioned in a patent case
Customer Sectors & Example Clients: Illumina's customers span a wide range of sectors including: genomic research facilities, universities and academic institutions, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, businesses focused on consumer genomics, and agriculture (agrigenomics). Example clients (educated guesses based on industry leaders and common users of NGS technology): Broad Institute, Mayo Clinic, Quest Diagnostics, LabCorp, Amgen, 23andMe.
New Customers / Segments They'Re Targeting: Illumina is actively targeting new customer segments by expanding clinical applications for its technology, particularly in oncology (Minimal Residual Disease or MRD, therapy selection) and other areas like rare diseases and NIPT screening. They are also focused on broadening their multi-omics offerings, including spatial biology with StrataMap Spatial and proteomics with SomaScan and SomaSeq, to provide more comprehensive biological insights. Furthermore, through their BioInsight platform and the Billion Cell Atlas initiative, they are specifically targeting pharmaceutical customers to advance AI-enabled drug discovery.
Sales Geographies And Expansion Plans: Illumina sells its products directly to clients across North America, Europe, Latin America, and the Asia-Pacific. They also partner with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. The company's reporting segments include "Rest of World organic growth" and specifically excludes Greater China due to its inclusion on China's unreliable entity list. In Q2 2026, the U.S.-Canada region showed particular strength in clinical growth, while slower growth was observed in Europe, the Middle East, and Latin America due to ongoing regional dynamics. Management emphasizes expanding market penetration within existing regions, especially in clinical applications, rather than explicitly disclosing plans to expand into entirely new geographies.
How Key Themes May Help/Hurt: Illumina is well-positioned to benefit from the buildout of the 'MedTech Long '26: Diagnostics & Early Detection' theme. Its next-generation sequencing (NGS) instruments are foundational to the global liquid biopsy and multi-omics testing infrastructure, directly supporting the development and adoption of highly effective diagnostic and early detection technologies. The increasing prevalence of chronic diseases, especially cancer, drives demand for advanced diagnostic solutions, which Illumina's clinical applications (oncology, rare diseases, NIPT) directly address. Advancements in genomics, AI, and multi-omics (like StrataMap Spatial and BioInsight's Billion Cell Atlas) further expand its market opportunities. Favorable regulatory developments, such as the MCED Act, are expected to enhance market access for multi-cancer early detection tests, indirectly boosting demand for Illumina's sequencing platforms. However, Illumina could be hurt by persistent reimbursement pressures and evolving payer policies for novel diagnostic tests, significant regulatory hurdles for new indications (like MRD and MCED), and intensifying competition in the diagnostics space, which could lead to pricing pressures and impact the market uptake of its instruments and consumables.

3 Main Long-Term Bull Details

Dominance and Expansion in Clinical Genomics: Illumina is experiencing sustained and robust growth in clinical markets, with clinical consumables growing mid-teens year-over-year and comprising approximately 65% of sequencing consumables revenue. The NovaSeq X platform continues to see strong demand and placements, especially in clinical settings, expanding the installed base and driving long-term consumables revenue for applications like oncology (MRD, therapy selection), rare diseases, and NIPT screening.
Continuous Innovation and Expanding Multi-omics Platform Value: Illumina is committed to continuous innovation, evidenced by the launch of the whole genome MRD research workflow and the StrataMap Spatial sequencing-based spatial workflow. The SomaLogic acquisition has brought SomaScan and SomaSeq offerings, and the BioInsight platform, including the Billion Cell Atlas, is leveraging AI for drug discovery. These innovations expand the utility of Illumina's ecosystem, ensuring its relevance and driving future demand by offering more comprehensive biological insights.
Strong Financial Trajectory and Operational Discipline: Despite a dynamic macro environment, Illumina delivered a strong Q2 2026, exceeding revenue and EPS guidance, and subsequently raised its full-year 2026 outlook for revenue growth and profitability. The company is making progress towards its 2027 targets of high single-digit revenue growth and continued margin expansion, reflecting disciplined execution and operational leverage, including managing inflationary pressures.

3 Main Long-Term Bear Details

Cautious Research and Academic Market Demand: Demand in research and academic markets remains cautious due to persistent funding uncertainty, leading to a 7% decline in Rest of World research and applied sequencing consumables in Q2 2026. While some late-quarter improvements were noted, it is too early to call a recovery, posing a continued headwind to a significant portion of Illumina's business and potentially impacting future innovation adoption.
Competitive Pressures and Pricing Dynamics: The competitive landscape continues to evolve, with ongoing discussions around aggressive pricing from new entrants and the need for volume discounts on NovaSeq X placements. While Illumina expresses confidence in its value proposition and market leadership, potential future pricing pressures and increased competition for market share, particularly as new technologies emerge, remain a long-term risk that could impact revenue growth and margin expansion.
Supply Chain and Inflationary Pressures: Illumina continues to face inflationary pressures related to freight costs and higher costs of electronic components and memory. While the company has taken mitigating actions by securing supply for several quarters, persistent supply chain issues or unmanaged cost increases could impact instrument production, gross margins, and overall profitability, despite efforts to absorb these costs.

Competitors And Differentiation: Illumina operates in a competitive landscape, facing new entrants and established players, particularly in lower-cost sequencing. Competitors may include companies like Roche (with AXELIOS 1) and others offering alternative sequencing technologies. Illumina differentiates itself by offering a comprehensive ecosystem of advanced genetic and genomic analysis tools, including its flagship NovaSeq X platform, which customers view as the platform to invest in for both current and future workflows. The company's strategy focuses on continuous innovation to deliver the highest quality insights at the lowest end-to-end cost, expanding into multi-omics capabilities (e.g., StrataMap Spatial, SomaScan/SomaSeq) and AI-enabled drug discovery (BioInsight/Billion Cell Atlas), and leveraging deep relationships with leading clinical customers and a large installed base to reinforce its market position.
Recent Performance & What The Market'S Focused On: Illumina delivered a strong Q2 2026, with revenue growing 9.5% year-over-year to $1.16 billion, or 8.1% on an organic basis excluding China, exceeding guidance. This performance was driven by robust demand in clinical markets, which saw sequencing consumables (ex-China) grow 15% year-over-year, and strong NovaSeq X placements, with over 95 units placed in the quarter. In contrast, research and academic markets remained cautious, with consumables declining 7% Rest of World. The company raised its full-year 2026 guidance, now expecting Rest of World organic revenue growth greater than 5% and diluted EPS of $5.30-$5.40. For Q3 2026, Illumina anticipates Rest of World organic revenue growth of approximately 4.5% and non-GAAP EPS of $1.33-$1.38. The market is focused on the sustainability of elevated NovaSeq X instrument placements and their translation into accelerated consumables revenue growth to support the high single-digit revenue target for 2027. Investors are also closely watching for signs of recovery in the research and academic markets, the adoption of new multi-omics offerings like StrataMap Spatial and BioInsight's Billion Cell Atlas, and Illumina's ability to achieve projected operating margin expansion in the second half of 2026 despite ongoing inflationary pressures.

Revenue Segments And Estimated Mix: {"segments":[{"segment_name":"Sequencing Consumables","estimated_mix":"~66.8%","source_or_comment":"Q2 2026 transcript (775M / 1160M)","yoy_or_trend_comment":"Up 5% YoY (reported and organic Rest of World basis); Clinical grew 15% ex-China; Research and applied declined 7% Rest of World."聯合國糧食及農業組織"},{"segment_name":"Sequencing Instruments","estimated_mix":"~10.8%","source_or_comment":"Q2 2026 transcript (125M / 1160M)","yoy_or_trend_comment":"Up 31% YoY (reported and organic Rest of World basis); Driven by NovaSeq X and MiSeq i100 sales."聯合國糧食及農業組織"},{"segment_name":"Sequencing Service and Other","estimated_mix":"~13.3%","source_or_comment":"Q2 2026 transcript (154M / 1160M)","yoy_or_trend_comment":"Up 14% YoY (reported and organic Rest of World basis); Higher data revenue from Billion Cell Atlas."聯合國糧食及農業組織"},{"segment_name":"Microarrays and Other","estimated_mix":"~9.1%","source_or_comment":"Q2 2026 transcript (105M / 1160M)","yoy_or_trend_comment":"Up 21% reported (includes SomaLogic revenue); Declined 4% on a Rest of World organic basis."聯合國糧食及農業組織"}]}
Product Brands: NovaSeq X Series
NovaSeq 6000 System
MiSeq i100 Series
MiSeq System
NextSeq 1000 & 2000 Systems
NextSeq 550 System
iSeq 100 System
TruPath
BioInsight
Billion Cell Atlas
5-Base Solution
DRAGEN Secondary Analysis
Illumina Connected Analytics
Infinium (microarray technology)
iScan System
fireflyGO
Trusight Oncology
Illumina DNA Prep
Pillar oncoReveal
TruSight Panels
AmpliSeq for Illumina
XLEAP-SBS chemistry
StrataMap Spatial
SomaScan
SomaSeq
whole genome MRD research workflow

Bull / Bear Details

Illumina maintains a bullish outlook, driven by robust Q2 2026 performance with revenue growing at its fastest rate, fueled by strong clinical market demand and

Thesis

Illumina maintains a bullish outlook, driven by robust Q2 2026 performance with revenue growing at its fastest rate, fueled by strong clinical market demand and continued NovaSeq X placements. Strategic expansion into multi-omics, including StrataMap Spatial and BioInsight's Billion Cell Atlas, enhances platform value and future growth. Despite persistent caution in research markets and inflationary cost pressures, raised 2026 guidance and commitment to high single-digit 2027 revenue growth reinforce its sustainable trajectory. (Updated: 2026-10-16)

Bull case

Illumina is experiencing robust and durable demand in clinical markets, which comprise approximately 65% of sequencing consumables revenue. Clinical sequencing consumables (ex-China) grew 15% year-over-year in Q2 2026, with U.S.-Canada growing over 20%. Over 95 NovaSeq X placements in the quarter, primarily to clinical customers, are expanding the installed base and will drive sustained consumables pull-through and long-term growth.
Illumina's innovation pipeline is expanding platform value through multi-omics capabilities and AI-enabled drug discovery. Recent launches include the StrataMap Spatial workflow and a whole genome MRD research workflow. Sustained proteomics momentum from SomaLogic's SomaScan/SomaSeq and BioInsight's Billion Cell Atlas, which has secured six pharma partners and is generating revenue, further broadens customer applications and future growth drivers.
Illumina delivered a strong Q2 2026, with revenue growing at its fastest rate and exceeding guidance, leading to a raised full-year 2026 outlook for Rest of World organic revenue growth (greater than 5%) and EPS ($5.30-$5.40). The company remains committed to its 2027 target of high single-digit revenue growth, reflecting disciplined execution, operational leverage, and a strong setup for continued consumable growth.

Bear case

Demand in research and academic markets remains cautious due to persistent funding uncertainty, leading to a 7% decline in Rest of World research and applied sequencing consumables in Q2 2026. While some late-quarter improvements were noted, management believes it is too early to call a recovery, posing a continued headwind to a significant portion of Illumina's business and potentially impacting future innovation adoption.
Near-term operating margins face pressure from inflationary costs, as Illumina absorbed higher freight and memory costs in Q2 2026. Memory prices are still rising and allocations continue to be strained. Additionally, slower clinical consumables growth in the Europe, Middle East, and Latin America region due to regional dynamics, and a muted mid-throughput instrument market due to the macro environment, could impact overall profitability and growth rates in certain segments.
The competitive landscape continues to evolve, with ongoing discussions around aggressive pricing from new entrants and the need for volume discounts on NovaSeq X placements. While Illumina expresses confidence in its value proposition and market leadership, potential future pricing pressures and increased competition for market share, particularly as new technologies emerge, remain a long-term risk that could impact revenue growth and margin expansion.

Bull / Bear Case

Bear Case: Demand in research and academic markets remains cautious due to persistent funding uncertainty, leading to a 7% decline in Rest of World research and applied sequencing consumables in Q2 2026, with management stating it's too early to call a recovery. Near-term operating margins face pressure from inflationary costs, as Illumina absorbed higher freight and memory costs in Q2 2026, and memory prices are still rising with strained allocations. Slower clinical consumables growth in the Europe, Middle East, and Latin America region due to regional dynamics, and a muted mid-throughput instrument market, could impact overall profitability. The competitive landscape continues to evolve with discussions around aggressive pricing from new entrants, posing a long-term risk to revenue growth and margin expansion. Additionally, a recent voluntary recall of some NovaSeq 6000Dx units due to a security vulnerability adds a minor operational concern.
Bull Case: Illumina is experiencing robust and durable demand in clinical markets, which comprise approximately 65% of sequencing consumables revenue, growing 15% year-over-year ex-China with U.S.-Canada exceeding 20%. Strong NovaSeq X placements, over 95 units in Q2 2026, are expanding the installed base and will drive sustained consumables pull-through and long-term growth. The company's innovation pipeline is expanding platform value through multi-omics capabilities (StrataMap Spatial, SomaScan/SomaSeq) and AI-enabled drug discovery via BioInsight and the Billion Cell Atlas, which has secured six pharma partners and is generating revenue. Illumina delivered a strong Q2 2026, exceeding guidance and raising its full-year 2026 outlook for Rest of World organic revenue growth (greater than 5%) and EPS ($5.30-$5.40), while remaining committed to high single-digit revenue growth in 2027.
More Compelling & Why: Bear Case. The current valuation, with a P/E ratio (TTM) of approximately 50.54x and an EV/FCF of 45.82x, appears significantly overvalued, trading 102.9% above its estimated fair value according to GuruFocus. The strongest argument for the bear case is that these high multiples are difficult to justify given persistent headwinds in research markets, ongoing inflationary pressures, and increasing competitive dynamics that could pressure future growth and margins. My view would flip if Illumina demonstrated sustained double-digit organic revenue growth and significant margin expansion that clearly outpaces inflationary pressures, leading to a more reasonable valuation relative to its growth prospects and industry peers.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
Research & Academic Market Demand Recovery	Recovery in research and academic markets is crucial for broader revenue growth and future innovation adoption, as this segment remains an important source of innovation and helps drive clinical adoption over time.	Year-over-year growth rate for Research and Applied sequencing consumables (Rest of World) in Q3 2026 and Q4 2026. Management expects mid to high single-digit declines for 2026.	Bullish: Research and Applied sequencing consumables (Rest of World) decline moderates to less than -5% year-over-year in Q3 2026, or turns positive. Bearish: Research and Applied sequencing consumables (Rest of World) decline remains at or worsens from -7% year-over-year in Q3 2026.	Illumina's Q3 2026 and Q4 2026 earnings conference calls and press releases.	NIH, Public Records: Government research funding announcements; r/labrats (Reddit): Discussions on lab funding and spending.	Bloomberg Terminal: Academic grant award data; FactSet: Research institution capital expenditure trends.
Adoption of StrataMap Spatial and Multi-omics Portfolio	Expansion into multi-omics, including StrataMap Spatial and BioInsight's Billion Cell Atlas, diversifies revenue streams, enhances platform value, and positions Illumina for future growth in emerging biological insights.	Commentary on initial customer adoption, order indications, and revenue contribution from StrataMap Spatial, SomaScan/SomaSeq, and BioInsight's Billion Cell Atlas in Q3 2026 and Q4 2026. Specifically, monitor new pharma partners for Billion Cell Atlas.	Bullish: Management reports strong initial customer adoption, significant order pipeline, or quantifiable revenue contribution (e.g., exceeding $10M) from StrataMap Spatial and other multi-omics products in Q3 2026. Bullish: Continued growth in BioInsight's Billion Cell Atlas program (e.g., adding more than 3 new partners per quarter, significant revenue contribution).	Illumina's Q3 2026 and Q4 2026 earnings conference calls and press releases, investor days.	Google Trends: Search volume for 'StrataMap Spatial' or 'Billion Cell Atlas'; Scientific publications citing Illumina's multi-omics platforms.	Revere: Web traffic to Illumina's multi-omics product pages; Thinknum: Job postings for multi-omics specialists at pharma companies.
Clinical Sequencing Consumables Revenue Growth (ex-China)	This segment is Illumina's primary growth driver, reflecting increasing adoption of sequencing-based diagnostics and more data-intensive applications, validating Illumina's strategy in high-value clinical markets.	Rest of World organic clinical sequencing consumables revenue growth rate in Q3 2026 and Q4 2026. Management expects mid-teens growth for the full year 2026.	Bullish: Clinical sequencing consumables (ex-China) growth remains at or above mid-teens year-over-year in Q3 2026. Bearish: Clinical sequencing consumables (ex-China) growth falls below 10% year-over-year in Q3 2026.	Illumina's Q3 2026 and Q4 2026 earnings conference calls and press releases.	NIH, Public Records: Genomics research funding trends; Google Trends: Search interest for 'sequencing diagnostics' or specific clinical applications (e.g., 'MRD testing').	IQVIA / Symphony Health: CPT code utilization for molecular diagnostic tests; Earnest Analytics: Diagnostic device sales data.
NovaSeq X Clinical Volume Transition & Pull-Through	Successful transition of clinical volume to NovaSeq X and strong pull-through per instrument are crucial indicators of platform adoption, utilization, and future high-margin consumables revenue.	Percentage of clinical volume transitioned to NovaSeq X in Q3 2026 and Q4 2026 (target 80-85% by end of 2026). Also, monitor NovaSeq X pull-through (currently above $1.3 million).	Bullish: Clinical volume on NovaSeq X reaches or exceeds 80% by Q3 2026, or pull-through remains at or above $1.3 million per instrument. Bearish: Clinical volume transition to NovaSeq X slows significantly (e.g., less than 79% by Q3 2026), or NovaSeq X pull-through declines below $1.2 million.	Illumina's Q3 2026 and Q4 2026 earnings conference calls and press releases.	Company investor presentations for updated metrics; Industry analyst reports on sequencing platform adoption.	Evercore ISI: Channel checks on NovaSeq X utilization; Cowen: Proprietary surveys on lab instrument adoption.
NovaSeq X Instrument Placements	Strong NovaSeq X placements expand the installed base, which is critical for driving future high-margin consumables revenue and signals robust market demand and leadership.	Number of NovaSeq X units placed in Q3 2026 and Q4 2026. Management expects elevated placements to continue in H2 2026.	Bullish: NovaSeq X placements in Q3 2026 remain at or above 90 units. Bearish: NovaSeq X placements fall significantly below 80 units in Q3 2026.	Illumina's Q3 2026 and Q4 2026 earnings conference calls and press releases.	Industry reports on sequencing instrument sales, competitor earnings calls for market commentary.	Third Bridge: Expert calls on sequencing instrument demand; AlphaSense: Transcripts of competitor earnings calls mentioning market share.

Key Reported Metrics, Reratings Triggers & Results3 rows

This segment has been a significant headwind due to funding uncertainty. A moderation in its decline or a return to growth would signal a broader market recover

Upcoming print · 2026-10-29

Key reported metrics			Rerating thresholds
Metric	Last period	Why it matters	What's needed for rerating	Rerating context	Earnings date
Research and Applied sequencing consumables (Rest of World) growth rate	declined 7%	This segment has been a significant headwind due to funding uncertainty. A moderation in its decline or a return to growth would signal a broader market recovery and alleviate pressure on overall revenue growth.	For Illumina (ILMN) to rerate higher, the Research and Applied sequencing consumables (Rest of World) growth rate needs to show a significant moderation in its decline, specifically improving to a decline of less than -5% year-over-year in Q3 2026, or ideally, turning positive. This would exceed management's current expectation of mid to high single-digit declines for 2026 and signal a recovery in the cautious research and academic markets.	This metric is a significant headwind for Illumina, reflecting persistent funding uncertainty in research markets. A moderation in its decline or a return to growth would signal a broader market recovery, alleviate pressure on overall revenue growth, and demonstrate easing cautiousness in a key segment, justifying a more optimistic valuation.	2026-10-29
Sequencing Instruments Revenue	$775 million (15% y/y growth ex-China)	Strong instrument placements, particularly of NovaSeq X, are crucial for expanding the installed base, which directly drives future, high-margin consumables revenue. This metric signals market leadership and customer investment in Illumina's platform.	For Illumina (ILMN) to rerate higher, Sequencing Instruments Revenue for Q3 2026 needs to exceed $125 million and demonstrate year-over-year growth significantly above the company's full-year guidance of 'low single digits' for instruments. This would be supported by NovaSeq X placements remaining at or above 90 units in Q3 2026, signaling continued strong demand and outperformance relative to moderated expectations.	Strong instrument revenue, driven by robust NovaSeq X placements, is crucial as it expands Illumina's installed base, which directly fuels future, high-margin consumables revenue. Exceeding expectations here validates market leadership, customer investment in the platform, and reinforces the long-term growth thesis, justifying a premium valuation.	2026-10-29
Clinical Sequencing Consumables Revenue (ex-China)	$775 million (15% y/y growth ex-China)	This metric is Illumina's primary growth driver, reflecting increasing adoption of sequencing-based diagnostics and more data-intensive applications. Sustained mid-teens growth validates the company's strategy in high-value clinical markets and drives overall revenue.	Clinical Sequencing Consumables Revenue (ex-China) needs to report year-over-year growth of 20% or higher in Q3 2026. This would demonstrate a reacceleration of growth, surpassing the 15% reported in Q2 2026 and aligning with the higher growth rates seen in Q1 2026 that previously fueled bullish sentiment.	Achieving 20%+ growth in clinical sequencing consumables ex-China would validate Illumina's strategy in high-value clinical markets and NovaSeq X utilization. This reacceleration would confirm durable demand, justify a premium valuation, and reinforce investor confidence in the company's long-term growth trajectory and market leadership.	2026-10-29

Last reported · 2026-07-30

Key reported metrics			Rerating thresholds			Earnings results
Metric	Last period	Why it matters	What's needed for rerating	Rerating context	Earnings date	Actual reported	Hit target?	Notes
Non-GAAP Diluted EPS	19%	As a key bottom-line metric, Non-GAAP Diluted EPS reflects Illumina's overall profitability and operational efficiency. Strong EPS growth indicates effective cost management and leverage from revenue growth, directly impacting shareholder value.	For the stock to rerate higher, Illumina's Non-GAAP Diluted EPS for Q2 2026 needs to exceed its guidance range of $1.20 to $1.25, ideally hitting $1.28 or higher, and the company should either raise or reaffirm the high end of its full-year 2026 guidance of $5.15 to $5.30.	Exceeding EPS expectations would confirm robust clinical market momentum and NovaSeq X adoption, demonstrating strong operational execution and mitigating concerns about research market softness and competitive pressures. This performance would justify a higher valuation multiple and reinforce investor confidence in Illumina's path to sustainable double-digit EPS growth.	2026-07-30	$1.31 (10% y/y growth)	Yes	Illumina reported Non-GAAP Diluted EPS of $1.31, exceeding its guidance range of $1.20 to $1.25 and the ideal target of $1.28 or higher. The company also raised its full-year 2026 diluted EPS guidance to $5.30-$5.40, an increase of $0.12 at the midpoint, which is above the high end of its prior guidance of $5.15 to $5.30. This strong performance and raised outlook were positive highlights of the earnings report, demonstrating robust operational execution.
NovaSeq X Placements	33.3%	High NovaSeq X placements indicate strong customer adoption of Illumina's flagship platform, which is crucial for driving future, high-margin consumables revenue. It signals market leadership and expansion into clinical workflows.	NovaSeq X Placements (representing the percentage of clinical volume transitioned to NovaSeq X) needs to reach 45-50% or higher in Q2 2026, demonstrating significant acceleration towards the 80-85% year-end target. Additionally, NovaSeq X instrument placements should exceed 80 units in Q2.	Hitting this threshold demonstrates accelerated adoption of Illumina's flagship NovaSeq X platform, crucial for driving future high-margin consumables revenue and confirming market leadership. It signals successful scaling of supply and strong progress towards the 80-85% clinical volume transition target by year-end, validating the company's growth strategy and competitive position.	2026-07-30	95+ units placed; 78% of clinical volume transitioned to NovaSeq X	Yes	Illumina reported placing more than 95 NovaSeq X instruments in Q2 2026, exceeding the rerating trigger of over 80 units. Additionally, approximately 78% of clinical volume has now transitioned to the NovaSeq X platform, significantly surpassing the 45-50% target for Q2 2026 and demonstrating strong progress towards the 80-85% year-end conversion goal. This indicates accelerated adoption and strong demand for the flagship platform, particularly among clinical customers.
Clinical Sequencing Consumables Revenue (ex China)	20%	This segment is a primary growth driver, making up over 65% of consumables revenue, reflecting increasing adoption of sequencing-based diagnostics and more data-intensive applications. Continued strong growth here validates Illumina's strategy in high-value clinical markets.	For Illumina (ILMN) to rerate higher, the Clinical Sequencing Consumables Revenue (ex China) metric needs to maintain or exceed its current 20% year-over-year growth rate in Q2 2026. This would align with recent analyst upgrades and their bullish sentiment, which anticipates another quarter near 20% growth to justify higher price targets.	This metric is a primary growth driver, reflecting increasing adoption of sequencing-based diagnostics and robust NovaSeq X utilization. Sustained growth at or above 20% validates Illumina's strategy in high-value clinical markets, justifying a premium valuation and confirming the bullish investment thesis.	2026-07-30	$775 million (15% y/y growth ex-China)	No	Clinical sequencing consumables revenue (ex-China) grew 15% year-over-year in Q2 2026, a deceleration from the 20% growth seen in the prior quarter. Management noted that while this was a slowdown, 'mid-teens growth is strong and is still beyond what we started the year with'. The company raised its full-year outlook for clinical markets towards the high end of its prior guidance, now expecting mid-teens growth for the year. The slight moderation in growth was attributed to 'some in and outs in, especially in the Middle East and Latin America'.

Key Questions

Can Illumina sustain elevated NovaSeq X instrument placements in the second half of 2026, and will the expanding installed base translate into the anticipated a

Can Illumina sustain elevated NovaSeq X instrument placements in the second half of 2026, and will the expanding installed base translate into the anticipated acceleration of consumables revenue growth to support the high single-digit revenue target for 2027, particularly as instrument growth moderates?

Question 2: Will the observed 'signs of improvement' in the research and academic markets translate into a meaningful moderation of the mid-to-high single-digit declines in sequencing consumables demand for the second half of 2026, or will cautiousness and funding uncertainty persist?
Question 3: Can Illumina successfully execute its cost actions and benefit from a favorable product mix shift to achieve the projected operating margin expansion in the second half of 2026, particularly the sequential step-up to approximately 24% in Q3, despite ongoing inflationary pressures from freight and memory costs?

Earnings Transcript Summary2 rows

2026-07-30 · 2026Q2 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Sustaining strong performance and clinical market momentum: Management highlighted a "great first half of 2026" and "another strong quarter in Q2," with revenue growing at the fastest rate since the CEO joined, driven by increasing demand in clinical applications. They noted that clinical markets, representing approximately 65% of sequencing consumables revenue, remained the primary growth driver, with broad-based Rest of World clinical growth and strong NovaSeq X placements expanding customer capacity for future consumable growth. 2. Expanding platform value through innovation and multi-omics capabilities: Jacob Thaysen emphasized efforts to "expand the value of our platform through new workflows and multi-omics capabilities." This includes the launch of the whole genome MRD research workflow, the StrataMap Spatial sequencing-based spatial workflow, and sustained proteomics momentum from SomaLogic's SomaScan and SomaSeq offerings. They are also expanding BioInsight with initiatives like the Billion Cell Atlas to advance AI-enabled drug discovery. 3. Achieving long-term strategic and financial targets: Management reiterated their commitment to executing against long-range targets, raising 2026 guidance for revenue growth and profitability. They expressed confidence in the path towards "high single-digit revenue growth in 2027" and reinforced progress towards their 2024 financial targets, citing a "healthy market with significant untapped opportunity."	Call Takeaway & ToneThe overall takeaway of the call was highly positive and confident. Illumina reported a strong Q2 2026 performance, exceeding revenue and EPS expectations, primarily driven by robust demand in clinical markets and continued high NovaSeq X placements. The tone was optimistic, with management expressing strong conviction in the durability of clinical growth, the value of their innovation pipeline (especially multi-omics and AI-enabled drug discovery), and their ability to achieve long-term financial targets. While acknowledging ongoing caution in research markets and inflationary pressures, they conveyed confidence in their operational discipline and strategic execution to mitigate these challenges and sustain growth.	Prior Quarter'S Y/Y Growth By SegmentFor Q1 2026, total revenue was up 4.8% year-over-year (1.2% on an organic basis). Sequencing consumables revenue was up 4% year-over-year (5% Rest of World organic). Clinical sequencing consumable demand, excluding China, grew 20%. Research and applied sequencing consumables, excluding China, declined 12%. Sequencing instruments revenue was up 9% year-over-year (10% Rest of World organic). Sequencing service and other revenue was up 7% year-over-year (5% Rest of World organic). The Microarrays business was down 20% on a Rest of World organic basis.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. Sustainability of NovaSeq X placements and 2027 growth outlook: Analysts questioned the continued high NovaSeq X installs and why the 2027 revenue growth target wasn't higher than "high single-digits" given the current momentum. Management responded that the "growth and the momentum we see in the clinical market will continue for years to come," driven by elevated placements leading to future consumable pull-through. They stated they are "still very committed to delivering on the high single-digit growth" for 2027 by building a strong value proposition. 2. Sequential slowdown in clinical consumables and potential headwind from NovaSeq 6000 decommissioning: Analysts noted a sequential slowdown in clinical consumables growth (from 20% in Q1 to 15% in Q2) and asked about potential "over-earning" on consumables as NovaSeq 6000s are eventually decommissioned. Management clarified that "we continue to see that we have an expansion of volume on the X, and we continue to see quite a number of the 6000s being in action," with some customers even purchasing 6000s, not seeing it as a true headwind. They attributed the slight moderation in clinical growth to "some in and outs in, especially in the Middle East and Latin America," while emphasizing that "mid-teens growth is strong and is still beyond what we started the year with." 3. Q3 guidance step-down, Q4 pacing, and impact of AI-related revenues: Analysts inquired why Q3 guidance showed a step-down from Q2's 8% growth and asked about Q4 pacing, including the impact of an extra week, and the contribution from AI-related revenues like BioInsight. Management explained that Q2 was "very strong" and Q3 typically sees "normal seasonality" as a slightly lower quarter than Q4. They noted that the extra week in Q4 would contribute "maybe half a point or so of revenue" largely from consumables. Regarding AI, they expressed excitement about BioInsight and the Billion Cell Atlas, stating they are "making money already from day one on this, both on top line and bottom line," and see a "significant opportunity over the next period of time."	Revenue SegmentsTotal revenue was up 9.5% year-over-year, and 6.5% on an organic basis, with Rest of World organic growth at 8.1%. Sequencing consumables revenue was up 5% year-over-year on both a reported and organic Rest of World basis. Clinical markets (ex-China) grew 15%, while research and applied markets (Rest of World) declined 7%. Sequencing instruments revenue was up 31% year-over-year on both reported and Rest of World organic basis. Sequencing service and other revenue was up 14% on both a reported and Rest of World organic basis. Microarrays and other revenue was up 21% reported (including SomaLogic revenue), but declined 4% on a Rest of World organic basis.

2026-04-30 · 2026Q1 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Disciplined Commercial Execution and Clinical Market Momentum: Management highlighted strong Q1 performance, exceeding guidance, driven by disciplined execution and robust demand in clinical markets. Clinical made up over 65% of sequencing consumables revenue, reflecting continued adoption of sequencing-based diagnostics and more sequencing-intensive applications, which is fueling NovaSeq X placements in clinical settings. 2. Product Innovation and Roadmap Updates: Jacob Thaysen emphasized R&D efforts, including the launch of TruPath for whole genome sequencing, significant customer interest in their spatial transcriptomics offering (on track for launch later this year), and the 18-month roadmap for NovaSeq X, which includes new flow cells (14B and 35B) and improved data quality (Q70). This demonstrates a commitment to expanding the value and capabilities of their platforms. 3. Progress Against Long-Term Strategy and Targets (including NovaSeq X Expansion): Management reiterated confidence in their strategy, noting that the NovaSeq X is central to scaling and expanding customer applications, thereby driving consumables growth. They are raising 2026 guidance and remain on track for their 2027 targets of high single-digit revenue growth, continued margin expansion, and double-digit to teens EPS growth. They also highlighted the successful SomaLogic acquisition and investments in BioInsight and the Billion Cell Atlas.	Call Takeaway & ToneThe overall takeaway of the call was highly positive and confident. Illumina had a strong start to 2026, exceeding Q1 guidance for revenue, margin, and EPS, primarily driven by robust demand in clinical markets and strong NovaSeq X placements. Management expressed confidence in their long-term strategy, emphasizing continuous innovation, NovaSeq X expansion, and disciplined operational execution to drive sustainable growth and margin expansion. While acknowledging ongoing cautiousness in research markets and some near-term inflationary pressures, they conveyed optimism about their ability to mitigate these challenges and achieve their long-range targets, leading to a raised full-year 2026 guidance.	Prior Quarter'S Y/Y Growth By SegmentFor Q4 2025, total revenue was up 5% year-over-year. Sequencing consumables revenue increased 8% year-over-year (11% excluding China). Clinical sequencing consumables, excluding China, grew 20% year-over-year. Sequencing instruments revenue was flat year-over-year (0%). Sequencing service and other revenue was up 4% year-over-year. Specific year-over-year growth percentages for 'Research and applied sequencing consumables (ex China)' and 'Microarrays business' were not explicitly provided in the Q4 2025 search results; however, research and academic demand was noted as subdued in Q4 2025.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. Full-year organic revenue guidance vs. Q1 outperformance: Analysts questioned why the full-year organic revenue guidance wasn't raised more significantly despite the strong Q1 beat, particularly in instruments and clinical. Management (Jacob and Ankur) responded that raising both top and bottom line guidance after only one quarter signals confidence, and the $20 million revenue guidance increase moves them towards the higher end of the previously stated range, representing approximately a 0.5 percentage point increase. 2. NovaSeq X instrument demand, mix, and pricing transition: Analysts pressed on the impressive NovaSeq X placements (over 80 in Q1), asking about the mix between clinical and research, the impact of the NovaSeq 6000 to NovaSeq X pricing transition on consumables, and the outlook for future placements. Management stated that over 60% of placements were clinical and largely incremental, not just conversions. They noted that most research volumes are already on the X, mitigating future price headwinds, and that they were supply-constrained in Q1 due to robust demand, expecting similar placement levels in Q2 with a strong pipeline for the back half. They acknowledged volume discounts for large multi-unit orders but emphasized the primary focus on driving consumables growth. 3. Operating margin progression and Q2 headwinds: Analysts inquired about the Q2 operating margin being lower than expected and the progression throughout the year, given specific headwinds like a higher instrument mix, inflationary pressures (component costs, freight), and a full quarter of SomaLogic. Management (Ankur) explained that mitigating actions are underway, starting in Q2, with their effects expected to become visible from Q3 into Q4, leading to an anticipated ramp-up in operating margin in the second half of the year.	Revenue SegmentsTotal revenue was up 4.8% year-over-year (1.2% on an organic basis). Sequencing consumables revenue was $726 million, up 4% year-over-year, with Rest of World organic growth of 5%. Clinical sequencing consumable demand, excluding China, grew 20%. Research and applied sequencing consumables, excluding China, declined 12%. Sequencing instruments revenue was $118 million, up 9% year-over-year (10% on a Rest of World organic basis). Sequencing service and other revenue was $151 million, up 7% year-over-year (5% on a Rest of World organic basis). The Microarrays business was down 20% on a Rest of World organic basis.

Transcript Tidbits2 rows

2026-07-30

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketRevenue grew at the fastest rate since the CEO joined the company, driven by increasing demand for Illumina's technology as customers expand clinical applications. Clinical markets now represent approximately 65% of sequencing consumables revenue and remained the primary growth driver, with broad-based growth across regions and applications, particularly strong in the U.S.-Canada region. The company expanded its multi-omics portfolio with the launch of StrataMap Spatial, a sequencing-based spatial workflow, and is seeing sustained proteomics momentum from SomaScan and SomaSeq offerings following the SomaLogic acquisition. Illumina is also expanding its BioInsight data and insights offerings to help pharmaceutical customers advance AI-enabled drug discovery, with the Billion Cell Atlas initiative having delivered over 300 million cells and secured six biopharma partners. The whole genome MRD research workflow was also recently launched and is in early access with select customers. Oncology continues to lead application growth, with a shift towards MRD driving momentum, while rare diseases and NIPT screening also show nice growth.	About CompetitionManagement expressed confidence in Illumina's value proposition and continued innovation on the NovaSeq X platform, stating that customers see it as the platform to invest in and that this combination is winning in a healthy market. The company believes its innovations continue to prove there is a lot of lead way in the NovaSeq X platform, making it the platform to invest in.	About The Broader IndustryCustomers in research and academic markets remain cautious due to funding uncertainty, although some signs of improvement were seen late in the quarter, it is too early to call a recovery. Slower growth was observed in the Europe, Middle East, and Latin America region for sequencing consumables in clinical markets, largely due to ongoing near-term dynamics in the Middle East. The mid-throughput instrument market is more muted due to the macro environment. Illumina operates in a healthy market with significant untapped opportunity. The company also absorbed higher freight and memory costs in the quarter, noting that memory prices are still rising and allocations continue to be strained.	Where Things Are HeadedIllumina is raising its 2026 guidance for revenue growth and profitability, expecting full-year rest-of-the-world organic revenue growth greater than 5%, up from the prior range of 2%-4%. The company anticipates the pace of growth in the second half to remain broadly consistent with the first half, with consumables revenue continuing to grow from a higher installed base, while instrument growth moderates against tougher comparisons. The expanding NovaSeq X installed base is expected to drive further consumables growth beyond 2026 and support a path towards high single-digit revenue growth in 2027. Full-year diluted EPS guidance is raised to $5.30-$5.40, an increase of $0.12 at the midpoint. For Q3 2026, the company expects rest-of-world organic revenue growth of approximately 4.5% and reported revenue of $1.14 billion-$1.16 billion, with non-GAAP EPS of $1.33-$1.38 and non-GAAP operating margin of approximately 24%. Elevated NovaSeq X instrument placements are expected to continue in the second half of the year, with some moderation in year-over-year growth rates. The majority of placements are expected to continue going into the clinical space. The fourth quarter is typically the largest quarter for the year, and there is an extra week in Q4 this year, which could contribute about half a point of revenue, largely from consumables.	Updates On ThemeDiagnostics	Broader Themes EmergingAI-enabled drug discovery is emerging as a significant theme, with Illumina expanding its BioInsight data and insights offerings to help pharmaceutical customers advance this area, leveraging sequencing, perturbation tools, compute power, and AI to build high-quality multi-omics data sets and interpretation tools. Inflationary pressures and supply chain costs are also a broader theme, as the company absorbed higher freight and memory costs in the quarter.	Bullish-Leaning Quotes (Short)Revenue grew at the fastest rate since I joined the company. We are raising our 2026 guidance for revenue growth and profitability. Demand for NovaSeq X remained high more than three years after launch, with more than 95 placements in the quarter. Clinical markets, which represent approximately 65% of sequencing consumables revenue, remained our primary growth driver. The momentum we are seeing, especially from our clinical customers, gives us greater confidence as we enter the second half. I'm still very committed to delivering on the high single-digit growth [for 2027]. The momentum we've had here in the first half, I think is going to speak to the opportunity ahead of us.	Bearish-Leaning Quotes (Short)Customers remain cautious as they navigate funding uncertainty. It's too early to call a recovery [in research and academic markets]. We saw slower growth in Europe, Middle East, and Latin America region, largely due to ongoing near-term dynamics in the region. We believe it's still too early to predict the timing of an end market recovery [for research and applied consumables]. We also absorbed higher freight and memory costs in this quarter. Mid throughput is more muted because of the macro environment.	HiringWe recently welcomed Michael Sullivan and Julie Coletti to our management team, adding deep commercial and legal experience as we scale the business. We are equally pleased to welcome David King and Dan Skowronski to our board. Their experience across healthcare, diagnostics, and R&D will be valuable as we advance our clinical and innovation priorities.

2026-04-30

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketClinical markets are driving growth, making up over 65% of sequencing consumables revenue, fueled by the expansion of sequencing-based diagnostics and more data-intensive applications. Customers are launching new assays with ongoing reimbursement progress, supporting broader adoption of sequencing in clinical decision-making. Demand for comprehensive genomic profiling and whole genome sequencing is growing, increasing sequencing intensity, with NovaSeq X playing a central role. TruPath, a new whole genome sequencing workflow, is gaining significant interest, especially in rare disease, by simplifying standard of care and consolidating multiple tests. Illumina is on track to launch its spatial transcriptomics offering later this year, which has shown high engagement from early access users for challenging sample types. The NovaSeq X roadmap includes new 14B and 35B flow cells, staggered runs, and Q70 performance improvements, offering more flexibility, throughput, and workflow efficiency. BioInsight and the Billion Cell Atlas program are accelerating discovery and supporting AI-driven models for drug discovery, with growing partner interest. Clinical NovaSeq X placements are largely incremental, rather than conversions, immediately driving top-line growth.	About CompetitionIllumina does not see a substantial change in the competitive environment and looks forward to competing when new offerings reach the market. The company acknowledges competitive pricing discussions around cost per genome (e.g., $150 price point) but is not ready to discuss 35B flow cell pricing yet, focusing on elasticity and volume growth. Illumina views 10x Genomics' spatial launch positively, believing it drives overall interest in spatial biology, and sees room for multiple players due to different technologies and customer segments.	About The Broader IndustryThe clinical market shows sustained strength, while research and academic markets remain cautious due to funding uncertainty. There is alignment in Washington D.C. regarding NIH funding commitment, which is expected to pick up during the year, though translation into actual spending on tools and consumables may take time. The industry is experiencing near-term inflationary pressures related to freight costs and electronic components. The NovaSeq X transition for research customers is largely complete (over 90% volume), meaning less price headwind when that market recovers.	Where Things Are HeadedIllumina is raising its 2026 revenue guidance to $4.52 billion to $4.62 billion, operating margin expectations to 23.4% to 23.6%, and non-GAAP diluted EPS to $5.15 to $5.30, reflecting Q1 outperformance and business strength. The company remains on track for its 2027 targets of high single-digit revenue growth, continued margin expansion, and double-digit to teens EPS growth. Clinical market momentum is expected to continue into the coming years, with NovaSeq X placements driving consumables revenue approximately six months after installation. NovaSeq X placements are expected to be similar to Q1 levels (80+ units) in Q2, with a robust pipeline for the back half of the year, leading to full-year placements "reasonably above" the initial range. Investments are being made to scale NovaSeq X supply through Q2 and Q3 due to strong demand. Mitigating actions for inflationary pressures are expected to become visible in Q3 and Q4, leading to margin improvement in the second half of the year. The majority of clinical volumes (80% to 85%) are expected to transition to NovaSeq X by the end of 2026. Improvement in the research market due to easing funding uncertainties is considered an upside to the current guidance.	Updates On ThemeDiagnostics	Broader Themes EmergingArtificial Intelligence (AI) is mentioned in the context of BioInsight and the Billion Cell Atlas for accelerating discovery and supporting AI-driven models for drug discovery. Inflationary Pressures are noted as impacting freight costs and electronic components, requiring mitigating actions. Government Funding Dynamics, specifically NIH funding, are discussed regarding their impact on research spending.	Bullish-Leaning Quotes (Short)We are off to a great start in 2026 with Q1 revenue, margin and EPS all coming in above our guidance range. Over 80 NovaSeq X placements in the quarter, approximately 20 more than Q1 '25, with year-over-year placements growth in both clinical and nonclinical markets. Clinical made up more than 65% of our sequencing consumables revenue in the quarter, driven by both the expansion of sequencing-based diagnostics and the increased use of more data-intensive applications. We see a long runway for continued growth in our clinical business. We are raising our 2026 guidance to reflect the Q1 outperformance. We also remain on track toward our 2027 targets and the investments we are making in R&D and product innovation position us to deliver high single-digit revenue growth, continued margin expansion and double-digit to teens EPS growth for years to come. In fact, during Q1, we were supply constrained on the number of NovaSeq X units that were placed as the demand continues to remain very robust. I think our placements of instruments shows that there's no freezing of any market that we are participating in at this point. We are around above $1.3 million of pull-through on the Xs. And we think that, that will continue to be at that level, if not above. We don't -- we're not seeing any signs of potential deceleration per se in that market. There's good momentum there.	Bearish-Leaning Quotes (Short)In research and academic markets, demand remains cautious as customers navigate funding uncertainty. Sequencing consumables in research and applied declined 12% ex China, reflecting continued uncertainty in the funding environment during the quarter. Microarrays business was down 20% on a Rest of World organic basis, largely due to specific large customers in direct-to-consumer segment. Our guide assumes operating margins of approximately 22%, reflecting higher mix of instruments revenue and related investments, near-term inflationary pressures related to freight costs and higher cost of electronic components and a full quarter of SomaLogic as well. One thing is to have released grants, but the other thing is to have it all translated into spending the money on actually tools and consumables. And there are definitely some cautiousness with our customers before they've truly understand how those grants -- who are getting the grants and how many grants you're getting, there will be some cautiousness in that space for a little while.	HiringNon-GAAP operating expenses were up 3% year-over-year, largely reflecting the addition of the SomaLogic team, indicating workforce expansion through acquisition.